Integra LifeSciences (NASDAQ:IART) Stock Price Crosses Below 50-Day Moving Average - What's Next?

Key Points

• Integra LifeSciences shares slipped below their 50-day moving average of $14.36, trading as low as $14.13 before last changing hands at $14.35.
• Analyst sentiment is cautious: MarketBeat reports an average “Reduce” rating and a $16.12 consensus price target. Recent calls included a Zacks downgrade to “strong sell” and BMO lowering its target to $14.
• The company’s latest quarterly EPS of $0.59 beat the $0.56 consensus estimate, while revenue of $411.18 million came in below expectations of $413.16 million.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $14.36 and traded as low as $14.13. Integra LifeSciences shares last traded at $14.35, with a volume of 1,071,198 shares traded.

Analysts Set New Price Targets

A number of brokerages have recently commented on IART. Zacks Research lowered shares of Integra LifeSciences from a "hold" rating to a "strong sell" rating in a research report on Monday, October 26th. BMO Capital Markets reiterated a "market perform" rating and issued a $14.00 price target (down from $15.00) on shares of Integra LifeSciences in a report on Thursday, October 22nd. Weiss Ratings upgraded Integra LifeSciences from a "sell (e+)" rating to a "sell (d+)" rating in a report on Monday, October 26th. Truist Financial set a $13.00 target price on Integra LifeSciences and gave the company a "hold" rating in a research report on Friday, October 23rd. Finally, Wells Fargo & Company set a $13.00 target price on Integra LifeSciences and gave the stock an "equal weight" rating in a report on Thursday, October 22nd. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Reduce" and a consensus price target of $16.12.

Integra LifeSciences Price Performance

The company has a market cap of $1.12 billion, a PE ratio of 84.41, a PEG ratio of 1.05 and a beta of 1.28. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.21. The stock's 50-day moving average is $14.36 and its 200 day moving average is $14.17.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.56 by $0.03. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. The business had revenue of $411.18 million for the quarter, compared to the consensus estimate of $413.16 million. During the same period in the prior year, the firm posted ($0.07) earnings per share. On average, equities analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Integra LifeSciences during the second quarter worth about $82,000. Integrated Wealth Concepts LLC purchased a new position in shares of Integra LifeSciences in the 2nd quarter valued at approximately $84,000. Fulcrum Asset Management LLP raised its position in shares of Integra LifeSciences by 15,420.0% in the 3rd quarter. Fulcrum Asset Management LLP now owns 13,968 shares of the life sciences company's stock valued at $232,000 after purchasing an additional 13,878 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in Integra LifeSciences by 27.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company's stock worth $134,000 after purchasing an additional 3,059 shares in the last quarter. Finally, Diversified Trust Co acquired a new stake in Integra LifeSciences in the 3rd quarter worth approximately $243,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences is a medical technology company that develops products for neurosurgery, surgical care and tissue repair. Its offerings include devices and instruments used in cranial surgery, neuromonitoring and wound reconstruction, as well as materials designed to support the repair or regeneration of tissue. The company's product portfolio includes dural repair products, cranial stabilization systems, surgical instruments and dermal regeneration products. Integra serves hospitals, surgeons and other healthcare providers in the United States and international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.